SWOG clinical trial number
CTSU/EAA173
Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Open
Abbreviated Title
Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Treatment
Dexamethasone
Daratumumab
Eligibility Criteria Expand/Collapse
SWOG has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.
Please contact CTSU directly by phone (888/823-5923) or on the CTSU website (http://ctsu.org) for more information and registration procedures.
Please contact CTSU directly by phone (888/823-5923) or on the CTSU website (http://ctsu.org) for more information and registration procedures.